Remeditex Ventures LLC stated that they own 6.6% of Venaxis Inc. (NASDAQ:APPY) in a Schedule 13G disclosure that was filed with the SEC on Monday, September 19th. The investor owns 295,210 shares of the stock worth about $1,322,541. The reporting parties listed on the disclosure included Remeditex Ventures LLC, Malachite Trust and Lyda Hill. The disclosure is available through the SEC website at this hyperlink.

Venaxis Inc. (NASDAQ:APPY) traded up 0.4487% during trading on Monday, reaching $4.5001. 101,355 shares of the company’s stock traded hands. The company has a 50 day moving average price of $3.44 and a 200-day moving average price of $3.14. The company’s market cap is $17.44 million. Venaxis Inc. has a 12-month low of $1.60 and a 12-month high of $6.65.

Venaxis Company Profile

Venaxis, Inc (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company’s test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis.

5 Day Chart for NASDAQ:APPY

Want to see what other hedge funds are holding APPY? Visit to get the latest 13F filings and insider trades for Venaxis Inc. (NASDAQ:APPY).

Receive News & Ratings for Venaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.